Nanalysis Scientific Corp (NSCI)

[crmar]

Thanks for posting this . I like the company and the management .
Lots of potential !


grts

[gever]

Looking forward to Q4 results.
Exciting times ahead.

[crmar]

What about the results guys ? It is a very young company but i like
what i see ....

[gever]

Sean Krakiwsky comments on the recent K-prime acquisition.

[W_vdm]

Seems like a good combination of skillsets and services to me.
K'(Prime) Technologies bringing sales network and skills along with a service organisation, which will is highly valuable to ramp up the sales of NSCI's products.

Now they got to make sure the production facility can handle the additional sales. Looking forward to it.

[ctkrod]

Another acquisition:

https://www.newswire.ca/news-releases/nanalysis-merges-with-k-prime-technologies-inc--850419567.html

[douginil]

Thanks for posting the link

[walterc]

Fellow investors,

Research Capital ($3B CAD Assets Under Management) has initiated coverage on NSCI with a price target of $1.90. I invite investors to read the full report HERE.

We continue to gain more momentum in terms of raising awareness of our exciting story and hope to have more good news to you in the weeks to come.



As always, please contact me with any questions, feedback, or inquiries via phone or email using the contact details below and thank you as always for your continued support. To read the latest new on Nanalysis, please navigate to our Company News page by clicking HERE.

Best regards,

Matt Sellers
Investor Relations
Nanalysis Scientific Corp.
TSXV:NSCI, OTCQX:NSCIF, FRA:1N1

Mobile: [phone] (Whatsapp)
Office: +1.403.769.9499

nanalysis.com


Bay 1, 4600 – 5 St. NE, Calgary, Alberta, Canada T2E 7C3
Connect with us on Twitter and LinkedIn

[walterc]

very interesting presentation , especially the Q&A session

[NEgoodlife]

That makes more sense. Thanks.

[walterc]

I think it will only be used to defend the shareprice against abnormal decreases.

[ctkrod]

Agreed.

[NEgoodlife]

Using funds in this manner to provide shareholder value is a very strong indicator of confidence. Thanks for sharing the news.

[walterc]

CALGARY, AB, Oct. 21, 2021 /CNW/ - Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), is pleased to announce that it has received conditional acceptance from the TSX Venture Exchange to make a Normal Course Issuer Bid ("NCIB") to purchase for cancellation, during the 12-month period starting October 25, 2021, up to 3,844,081 of the Common Shares, representing 5% of the Common Shares outstanding as of October 25, 2021. The program will end on October 24, 2022, the maximum amount of Common Shares is purchased before then or Nanalysis provides earlier notice of termination.
nanalysis logo (CNW Group/Nanalysis Scientific Corp.)
The purchase and payment for the Common Shares will be made by Nanalysis through the facilities of the TSX Venture Exchange. Research Capital Corp has been selected as Nanalysis' agent for the NCIB. The price paid for the Common Shares will be, subject to NCIB pricing rules contained in securities laws, the prevailing market price of such Common Shares on the TSX Venture Exchange at the time of such purchase. Nanalysis intends to fund the purchases out of available cash.
Nanalysis believes that the market price of its Common Shares may not reflect their underlying value and the Board of Directors has authorized this initiative because, in the Board's opinion, the proposed purchase of Common Shares pursuant to the NCIB could constitute an appropriate use of Nanalysis' funds, and the repurchase of its Common Shares is one way of creating shareholder value and provides corporate flexibility.
To the knowledge of Nanalysis, no director, senior officer or other insider of the Nanalysis currently intends to sell any Common Shares under the NCIB. However, sales by such persons through the facilities of the TSX Venture Exchange may occur if the personal circumstances of any such person changes or any such person makes a decision unrelated to these NCIB purchases. The benefits to any such person whose Common Shares are purchased would be the same as the benefits available to all other holders whose Common Shares are purchased.


•

[Oleblue]

You can still listen to the webinar, just sign up.

[crmar]

I will , thank you !

[walterc]

I recommend to listen to the video once it is out. Very inspiring

[crmar]

Thanks for posting this Walter , i bought the stock 3 months ago , i have the feeling this is a very hidden hidden hidden stock with a good management . Is there strong competition in what they do ?

thank you

[walterc]

from Martin Gagel

I'll be posting the webinar onto YouTube this weekend.

Here's my channel, and please subscribe and you'll be notified when it gets posted.
I publish it on YouTube on Sunday morning Pacific Time - I'm in Vancouver.
YouTube - Radius Research

[walterc]

I asked for a reply

This is the mail I sent them

One of the best webinars I have followed in my career . You guys are getting better everytime. .I learn something more everytime I listen.
I also have to congratulate the interviewer with asking the right questions.
Happy to b e a shareholder here and holding very tight to my shares.

[douginil]

Thanks Walter for the comment about the webinar. It would be appreciated if you posted a link to a replay if it is made available.

Thanks Doug

[walterc]

Just finished listening to one of the best webinars I ever participated. Bot Sean and Luke were outstanding and the interviewer asked the right questions. Hopefully there will be a replay. The shareprice is going to follow the LWLG pattern in the next years.

[Oleblue]

LD Micro Presentation

https://me21.mysequire.com/recording?session_id=e5f371a2-9484-4668-b7af-07ce473dd83e

[crmar]

Thanks Walter ...bedankt .

[walterc]

yes indeed

Elysee will benefit in 2022 from being in US Vanadium.

[crmar]

Thanks for writing this Walter , what about elysee development comp ?
If i am right they presented the same day , do you see there potential ?

thank you

[walterc]

no video was made

it was this presentation with afterwards Q&A

https://static1.squarespace.com/static/5707ede0d210b8708e037a1e/t/6127cff9adffe444e82ea3d2/1629999099902/Nanalysis+Scientific+Corp+pres+v5.1.pdf

[W_vdm]

Hello Walter,

Are these presentations accessible for public audience/retail investors?
If so, is there somewhere additional information can be found?

Thanks in advance

[gever]

Indeed, very positive and informative report, lots of information and great prospects.
I'm going to read it a 3rd time to let all the positive info sink down.
It for sure puts a heavy burden on management's shoulders to live up to the expectations put forward.

Come on Sean, you can make it happen.
Smash that puck!!!

[walterc]

we have a presentation in Antwerp next Monday and Tuesday in Utrecht.

surprised there is so litlle reaction on this excellent report. This company is a jewel in the making

[ctkrod]

New research report out:

https://advisor.echelonpartners.com/research/content/nanalysisinitiation09212021.pdf

[ombowstring]

Thanks for the info.

[reading]

Not so relevant at this stage for this company I would say, but it was a 220k profit. Much more important is the development of unearned income, backlog and cash situation. The execution of Business plan seems almost perfect, very nice to see. Remains strong buy, as this might be a take-over target as well.

[ombowstring]

After looking through the Q2 results, I couldn't figure out if they made a profit or had a loss.

[ctkrod]

Things seem to be humming along nicely. Thanks for the link.

[gever]

Sean Krakiwsky comments on Q2 financial results and future outlook.

[gever]

Nanalysis Announces Q2 Financial Results
https://www.newswire.ca/news-releases/nanalysis-scientific-corp-reports-second-quarter-2021-financial-results-804148799.html

[gever]

Nanalysis' vision on future medical applications.

[cleverrox]

These valuations from Stonegate are ridiculously conservative. They using EV/S ratios on monster companies growing 15% a year. Yeah, if you are growing 15% a year are probably going to get an EV/S of 6. If you are growing at 100% a year, you have to throw that out the window. A better comparison would be ISRG, growing at 20% a year with EV/S of 27.

At minimum NSCI is going to deserve an EV/S of 20. If they make the $28M CAD estimate in 2022 from Stonegate, that should be multiplied by a minimum EV/S of 20 for a value of $560M CAD / 80M shares = $7 a share CAD.

[TrendTrade2016]

calling tops is a traders #1 focus....buying supports comes in second!!!

[gfp927z]

>>> Nanalysis Scientific Corp. Announces $8 Million "Bought Deal" Public Offering


Yahoo Finance

July 29, 2021


https://finance.yahoo.com/news/nanalysis-scientific-corp-announces-8-120400545.html


CALGARY, AB, July 29, 2021 /CNW/ - (the "Company" or "Nanalysis"), (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1) is pleased to announce that it has entered into an agreement with a syndicate of underwriters led by Echelon Wealth Partners Inc. (the "Underwriters") pursuant to which the Underwriters have agreed to purchase 6,666,700 units (the "Units") from the treasury of the Company, at a price of $1.20 per Unit (the "Issue Price") and offer them to the public by way of a short form prospectus for total gross proceeds of approximately $8,000,000 (the "Offering"). Each Unit will consist of one common share of the Company (each a "Common Share") and one-half of one common share purchase warrant (each full warrant, a "Warrant" and collectively the "Warrants"). Each whole Warrant shall entitle the holder thereof to acquire one Common Share for an exercise price of C$1.70 for period 24 months following the Closing Date.

The Company has granted the Underwriters an option to purchase up to an additional 15% of the Units at the Issue Price. The Over-Allotment Option may be exercised in whole or in part to purchase Common Shares, Warrants or Units as determined by the Underwriters upon written notice to the Company at any time up to 30 days following the Closing Date (the "Over-Allotment Option").

The Company intends to use the net proceeds of the Offering for sales, marketing, research and development, acquisitions, general administrative and working capital purposes.

The Offering will be completed (i) by way of a short form prospectus of the Company to be filed in British Columbia, Alberta, and Ontario, (ii) on a private placement basis in the United States pursuant to exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and (iii) outside Canada and the United States on a basis which does not require the qualification or registration of any of the Company's securities under domestic or foreign securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Concurrently with the Offering the Company may conduct a non-brokered private placement for up to $5,000,000 of Units issued on the same terms as the Offering.

The Offering is expected to close on or about August 25, 2021, or such other date as the Company and the Underwriters may agree, and is subject to customary closing conditions, including the approval of the securities regulatory authorities and the TSX Venture Exchange.

About Nanalysis Scientific Corp. (TSXV: NSCI , OTCQX: NSCIF, FRA: 1N1)

Nanalysis trades on the TSX Venture Exchange (TSXV) in with ticker symbol ' NSCI ' ,Over the Counter (OTC) in under the ticker symbol ' NSCIF ', and on the Frankfurt Exchange (FRA) under the symbol ' 1N1 '.

Nanalysis is an international business focused on capitalizing its proprietary technologies in magnetic resonance (MR) that go into NMR spectrometers and magnetic resonance imaging (MRI). Nanalysis operates out of two subsidiaries, Nanalysis Corp. and RS2D S.A.S. (RS2D).

Nanalysis Corp. is an industry leader in developing and manufacturing compact MR spectrometers for laboratory and industrial markets. Its advanced 60 and 100 MHz spectrometers require no liquid helium or other cryogens. These devices are used by chemical professionals spanning a wide variety of industries, including oil and gas, chemical, mining, pharmaceutical, and biotechnology.

Through its European subsidiary RS2D, the Company's electronic boards and software are used in conventional NMR and MRI equipment and are being incorporated into next-gen MRI systems as well as miniaturized MRI devices.

<<<

[ombowstring]

WHY THE SLIDE IN THE SHARE PRICE?

[walterc]

DALLAS, TX / ACCESSWIRE / July 26, 2021 / Nanalysis Scientific Corp. (TSXV:NSCI): The full report can be accessed by clicking on the following link:http://stonegateinc.com/reports/NSCI.V Initiation.pdf

COMPANY DESCRIPTION
Nanalysis Scientific Corp., develops, manufactures, and sells compact nuclear magnetic resonance (NMR) spectrometers and magnetic resonance imaging (MRI) equipment. The Company has a 10-year history as a global developer and supplier of portable nuclear magnetic resonance spectrometers for the industrial instrumentation market. Its products enhance analytical capabilities in quality control, research, teachings, and industrial environments through increasing availability of high-resolution NMR testing at fractional pricing in portable benchtop tools. The Company sells its products globally and is headquartered in Calgary, Canada. Furthermore, management notes that 30% of shares are held by employees.

COMPANY SUMMARY

Unique technology platform looking to disrupt the market - Many NMR systems are large, expensive, complex, unsafe and often environmentally unfriendly. Additionally, there are many industries that have a "traditional" way of analyzing samples, based on a technique or instrument(s) that have often excluded NMR based products due to limited access to NMR systems. While the scientific instrumentation market has been transitioning slowly toward smaller, compact systems, the market remains ripe for disruption. Nanalysis, through its proprietary, innovative product lines, is addressing unmet needs of customers in a variety of applications and industries. Nanalysis product is compact, inexpensive, simple to use, as safe to operate as a laptop, and environmentally friendly.

Large market opportunity - According to SDi's 2021 Global Assessment Report, the scientific instrumentation market will exceed $69B in 2021 and is expected to grow by over 5% per year. Furthermore, about $1B is spent on NMR testing equipment. Management believes the NMR market can grow by several billion dollars per year over the next five years driven by (1) the miniaturization of the technology should expand its use in many additional laboratories leading to standardization; and (2) new, industry specific applications that in the past, did not use scientific instrumentation.

Nanalysis' products are patent protected - Importantly, Nanalysis products are patent protected and uses proprietary hardware, software, algorithms and are further secured by technology know-how and trade secrets. These protections were developed over the past 10-15 years via its innovation, customer feedback, and manufacturing experience.

Growth strategy points to further growth - The Company's strategy is focused on organic growth and supplemented with M&A. On the organic side, Nanalysis will focus on innovation of new, best-in-class products and seek additional OEM relationships to collaborate and jointly develop new analytical solutions. The M&A strategy will seek tuck-in type acquisitions of complimentary business to drive scale economics such that the whole is worth more than the sum of its parts.

Strong sales backlog - At the end of Q121, Nanalysis has a backlog of 22 units of the 100 MHz NMRs, after sales of 6 units in Q121. On the balance sheet, unearned revenue grew from $2.9M at Q420 end to $3.9M at Q121.

Valuation - Given the early ramp in revenues, we are using an EV/S multiple analysis. Based on our F22 revenue estimate, we arrive at a valuation range of CAD$1.25 to CAD$2.95, with a mid-point of CAD$2.10. See page 6 for further details.

About Stonegate Capital Partners
Stonegate Capital Partners is a Dallas-based corporate advisory firm dedicated to serving the specialized needs of small-cap public companies. Since our inception, our mission has been to find innovative, undervalued public companies for our network of leading institutional investors who seek high-quality investment opportunities.

CONTACT:
Stonegate Capital Partners
[e-mail]
[phone]

SOURCE: Stonegate Capital Partners



View source version on accesswire.com:
https://www.accesswire.com/657102/Stonegate-Capital-Partners-Initiates-Coverage-on-Nanalysis-Scientific-Corp-TSXVNSCI

[ctkrod]

Looks like they’re executing their plan well. Great to see.

[walterc]

very positive strategic acquisition

well done

[gever]

https://www.newswire.ca/news-releases/nanalysis-acquires-new-york-based-software-company-880573074.html


"We are pleased to announce that we have acquired 100 percent of One Moon Scientific, a New York based magnetic resonance software company. This acquisition opens up new industry verticals for hardware sales and allows for software licensing and SAAS revenue.

One Moon Scientific specializes in a suite of software tools to streamline and automate Magnetic Resonance (“MR”) data analysis and management. Originally developed at a leading pharmaceutical company, this advanced software platform was designed from the ground up to provide routine, high-performance data processing and fill niches in MR data analysis, including making use of machine learning and database construction/search algorithms.

Nanalysis bought One Moon Scientific for $625,000 USD, of which $275,000 will be paid in cash and $350,000 will be paid through the issuance of four promissory notes. The contract was signed on July 21, 2021 by all parties. Final closing is scheduled for Wednesday, July 28th, 2021."

[Spin_Doctor]

I hope you like the news we put out this evening.

[Spin_Doctor]

You're very welcome sir. Happy to help.

[The Dutchman]

Hi Matt,
thanks for the info, solid looking.
R

[gever]

Why is mass commercialization around the corner, you may wonder.
Have a look at the testimonials below.

https://www.nanalysis.com/industrial-testimonials

"... we used to outsource our product analysis to a university for evaluation on a high-field NMR spectrometer. This outsourcing cost was high, up to $50 000/year. When I heard about benchtop NMR I was curious to determine if it would be suitable for observing hydrolysis and oxidation decomposition products in our phosphites - and it was. Now we run all our products in our own R&D lab – not only saving us time and money, but also giving us flexibility to acquire conformational NMR data on samples that we wouldn’t have deemed necessary to outsource.”